Influence of ex vivo purging with CliniMACS CD34+ selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma

British Journal of Haematology

Volumn 164, Issue 4, 2014, Pages 555-564

  Yahng, Seung Ah ^a   Yoon, Jae Ho ^b   Shin, Seung Hwan ^b   Lee, Sung Eun ^b   Cho, Byung Sik ^b   Eom, Ki Seong ^b   Kim, Yoo Jin ^b   Lee, Seok ^b   Kim, Hee Je ^b   Min, Chang Ki ^b   Kim, Dong Wook ^b   Lee, Jong Wook ^b   Min, Woo Sung ^b   Park, Chong Won ^b   Kim, Yonggoo ^c   Cho, Seok Goo ^b  

^a Bupyeong gu   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Autologous stem cell transplantation; CliniMACS; ex vivo purging; Lymphoma

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CD34 SELECTION; CYTOMEGALOVIRUS; EX VIVO STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIRUS REACTIVATION;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINIMACS; EX VIVO PURGING; LYMPHOMA;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; BONE MARROW PURGING; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892953145     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12664     Document Type: Article

References (35)

1. Altes, A., Sierra, J., Esteve, J., Martin-Henao, G., Marin, P., Sureda, A., Briones, J., Martino, R., Villamor, N., Colomer, D., Carreras, E., Garcia, J., Brunet, S. & Montserrat, E. (2002) CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Experimental Hematology, 30, 824-830.
2. Alvarnas, J.C. & Forman, S.J. (2004) Graft purging in autologous bone marrow transplantation: a promise not quite fulfilled. Oncology (Williston Park, NY), 18, 867-876; discussion 876-868, 881, 884.
3. Apostolidis, J., Gupta, R.K., Grenzelias, D., Johnson, P.W., Pappa, V.I., Summers, K.E., Salam, A., Adams, K., Norton, A.J., Amess, J.A., Matthews, J., Bradburn, M., Lister, T.A. & Rohatiner, A.Z. (2000) High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. Journal of Clinical Oncology, 18, 527-536.
4. Benekli, M., Hahn, T., Shafi, F., Qureshi, A., Alam, A.R., Czuczman, M.S., Bernstein, Z.P., Chanan-Khan, A.A., Becker, J.L. & McCarthy, P.L. (2003) Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplantation, 32, 139-143.
5. Bierman, P.J., Sweetenham, J.W., Loberiza, F.R. Jr, Taghipour, G., Lazarus, H.M., Rizzo, J.D., Schmitz, N., van Besien, K., Vose, J.M., Horowitz, M. & Goldstone, A. (2003) Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 21, 3744-3753.
6. Bomberger, C., Singh-Jairam, M., Rodey, G., Guerriero, A., Yeager, A.M., Fleming, W.H., Holland, H.K. & Waller, E.K. (1998) Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood, 91, 2588-2600.
7. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
8. Davis, T.A., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. & Levy, R. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 3135-3143.
9. De Rosa, L., Lalle, M., Pandolfi, A., Ruscio, C. & Amodeo, R. (2002) Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission. Annals of Hematology, 81, 575-581.
10. Despres, D., Flohr, T., Uppenkamp, M., Baldus, M., Hoffmann, M., Huber, C. & Derigs, H.G. (2000) CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device. Journal of Hematotherapy and Stem Cell Research, 9, 557-564.
11. Flohr, T., Hess, G., Kolbe, K., Gamm, H., Nolte, H., Stanislawski, T., Huber, C. & Derigs, H.G. (2002) Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplantation, 29, 769-775.
12. Gribben, J.G., Freedman, A.S., Neuberg, D., Roy, D.C., Blake, K.W., Woo, S.D., Grossbard, M.L., Rabinowe, S.N., Coral, F., Freeman, G.J., Ritz, J. & Nadler, L.M. (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New England Journal of Medicine, 325, 1525-1533.
13. Gyan, E., Foussard, C., Bertrand, P., Michenet, P., Le Gouill, S., Berthou, C., Maisonneuve, H., Delwail, V., Gressin, R., Quittet, P., Vilque, J.P., Desablens, B., Jaubert, J., Ramee, J.F., Arakelyan, N., Thyss, A., Molucon-Chabrot, C., Delepine, R., Milpied, N., Colombat, P. & Deconinck, E. (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood, 113, 995-1001.
14. Hardingham, J.E., Kotasek, D., Sage, R.E., Gooley, L.T., Mi, J.X., Dobrovic, A., Norman, J.E., Bolton, A.E. & Dale, B.M. (1995) Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. Journal of Clinical Oncology, 13, 1073-1079.
15. van Heeckeren, W.J., Vollweiler, J., Fu, P., Cooper, B.W., Meyerson, H., Lazarus, H.M., Simic, A., Laughlin, M.J., Gerson, S.L. & Koc, O.N. (2006) Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. British Journal of Haematology, 132, 42-55.
16. Holmberg, L.A., Boeckh, M., Hooper, H., Leisenring, W., Rowley, S., Heimfeld, S., Press, O., Maloney, D.G., McSweeney, P., Corey, L., Maziarz, R.T., Appelbaum, F.R. & Bensinger, W. (1999) Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood, 94, 4029-4035.
17. Joshi, S.S., Kessinger, A., Mann, S.L., Stevenson, M., Weisenburger, D.D., Vaughan, W.P., Armitage, J.O. & Sharp, J.G. (1987) Detection of malignant cells in histologically normal bone marrow using culture techniques. Bone Marrow Transplantation, 1, 303-310.
18. Kewalramani, T., Zelenetz, A.D., Teruya-Feldstein, J., Hamlin, P., Yahalom, J., Horwitz, S., Nimer, S.D. & Moskowitz, C.H. (2006) Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. British Journal of Haematology, 134, 202-207.
19. Kreissman, S.G., Seeger, R.C., Matthay, K.K., London, W.B., Sposto, R., Grupp, S.A., Haas-Kogan, D.A., Laquaglia, M.P., Yu, A.L., Diller, L., Buxton, A., Park, J.R., Cohn, S.L., Maris, J.M., Reynolds, C.P. & Villablanca, J.G. (2013) Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet Oncology, 14, 999-1008.
20. Laurenti, L., Sora, F., Piccirillo, N., Chiusolo, P., Cicconi, S., Rutella, S., Serafini, R., Garzia, M.G., Leone, G. & Sica, S. (2001) Immune reconstitution after autologous selected peripheral blood progenitor cell transplantation: comparison of two CD34+ cell-selection systems. Transfusion, 41, 783-789.
21. Lemoli, R.M., Curti, A. & Tura, S. (1999) Negative selection of autologous peripheral blood stem cells. Baillière's Best Practice and Research. Clinical Haematology, 12, 57-69.
22. Leonard, B.M., Hetu, F., Busque, L., Gyger, M., Belanger, R., Perreault, C. & Roy, D.C. (1998) Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood, 91, 331-339.
23. Lopez, M. & Beaujean, F. (1999) Positive selection of autologous peripheral blood stem cells. Baillière's Best Practice and Research. Clinical Haematology, 12, 71-86.
24. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
25. Ringhoffer, M., Wiesneth, M., Harsdorf, S., Schlenk, R.F., Schmitt, A., Reinhardt, P.P., Moessner, M., Grimminger, W., Mertens, T., Reske, S.N., Dohner, H. & Bunjes, D. (2004) CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. British Journal of Haematology, 126, 527-535.
26. Rodriguez, J., Gutierrez, A., Martinez-Delgado, B. & Perez-Manga, G. (2009) Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Critical Reviews in Oncology Hematology, 71, 181-198.
27. Schumm, M., Lang, P., Taylor, G., Kuci, S., Klingebiel, T., Buhring, H.J., Geiselhart, A., Niethammer, D. & Handgretinger, R. (1999) Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. Journal of Hematotherapy, 8, 209-218.
28. Sharp, J.G., Joshi, S.S., Armitage, J.O., Bierman, P., Coccia, P.F., Harrington, D.S., Kessinger, A., Crouse, D.A., Mann, S.L. & Weisenburger, D.D. (1992) Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood, 79, 1074-1080.
29. Sharp, J.G., Kessinger, A., Mann, S., Crouse, D.A., Armitage, J.O., Bierman, P. & Weisenburger, D.D. (1996) Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. Journal of Clinical Oncology, 14, 214-219.
30. Thirukkumaran, C.M., Russell, J.A., Stewart, D.A. & Morris, D.G. (2007) Viral purging of haematological autografts: should we sneeze on the graft? Bone Marrow Transplantation, 40, 1-12.
31. Vescio, R., Schiller, G., Stewart, A.K., Ballester, O., Noga, S., Rugo, H., Freytes, C., Stadtmauer, E., Tarantolo, S., Sahebi, F., Stiff, P., Meharchard, J., Schlossman, R., Brown, R., Tully, H., Benyunes, M., Jacobs, C., Berenson, R., DiPersio, J., Anderson, K. & Berenson, J. (1999) Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood, 93, 1858-1868.
32. Vose, J.M., Bierman, P.J., Lynch, J.C., Atkinson, K., Juttner, C., Hanania, C.E., Bociek, G. & Armitage, J.O. (2001) Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation, 7, 680-687.
33. Watts, M.J., Somervaille, T.C., Ings, S.J., Ahmed, F., Khwaja, A., Yong, K. & Linch, D.C. (2002) Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. British Journal of Haematology, 118, 117-123.
34. Weisdorf, D.J., Haake, R., Miller, W.J., McGlave, P.B., LeBien, T.W., Vallera, D.A., Lasky, L.C., Kim, T.H., Peterson, B.A., Ramsay, N.K., Kersey, J.H. & Hurd, D.D. (1991) Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging. Bone Marrow Transplantation, 8, 135-142.
35. Williams, C.D., Goldstone, A.H., Pearce, R.M., Philip, T., Hartmann, O., Colombat, P., Santini, G., Foulard, L. & Gorin, N.C. (1996) Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. Journal of Clinical Oncology, 14, 2454-2464.